The Biogen company has dissected the entire human CR1 molecule with a series of mouse MoAbs, some of which targeted both the EGF-like domain and CFC domains and have proven to block human tumor cell growth in cell culture and in xenograft nude mouse models [52,53]. This evidence concerns the gene CR1 and neoplasm.